BIO Uses Biomanufacturing Executive Order To Argue Against Waiving Patent Protections

By John Wilkerson / September 28, 2022 at 3:51 PM
The Biotechnology Industry Organization is using the president’s recent executive order on domestic biomanufacturing as ammunition against a waiver of patent protections for COVID-19 treatments and diagnostics abroad. The World Trade Organization in June partially waived patent protections for COVID-19 vaccines , and WTO members are considering expanding that waiver to coronavirus treatments and diagnostics. The Biden administration backed the initial waiver to the Trade-Related Aspects of Intellectual Property Rights, but it has kept quiet about expanding the TRIPS waiver...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.